insights_auto
Why is DUL up 5,20%?
Dive Deeperchevron_right
DUL:ETR
Alnylam Pharmaceuticals, Inc.
€206,50
arrow_upward
+5,20%(+10,20) 1D
9 ຕ.ລ., 17 ໂມງ 35 ນາທີ 58 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€200,20
High
€206,50
Low
€200,10
Mkt. cap
31,13 ຕື້
Avg. vol.
40,00
Volume
5,00
52-wk high
€417,40
52-wk low
€177,10
No. of employees
2 ພັນ
Open
€200,20
High
€206,50
Low
€200,10
Mkt. cap
31,13 ຕື້
Avg. vol.
40,00
Volume
5,00
52-wk high
€417,40
52-wk low
€177,10
No. of employees
2 ພັນ
News stories
From web sources and news partners
Yahoo Finance
·
1 ມື້ກ່ອນ
Alnylam vs. Ionis: Here's the Better Bad-News Buy
ChartMill
·
2 ມື້ກ່ອນ
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
AD HOC NEWS
·
3 ມື້ກ່ອນ
Alnylam Pharmaceuticals stock gets a Strong Buy upgrade from Zacks Research
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.